FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171550055> ?p ?o ?g. }

• W3171550055 endingPage "1517" @default.
• W3171550055 startingPage "1517" @default.
• W3171550055 abstract "1517 Background: The Oncology Care Model (OCM) is a voluntary, episode-based alternative payment model for cancer care launched by the Centers for Medicare & Medicaid Services in July 2016. OCM incentivizes participating practices to reduce spending during chemotherapy treatment while maintaining quality of care. We evaluated the impact of OCM on the use of costly supportive care medications. Methods: Using 100% Medicare claims (2013-2019), we evaluated use of outpatient supportive care medications during chemotherapy episodes assigned to OCM practices (n = 186) or propensity-matched comparison practices (n = 534). For bone supportive medications, we evaluated use of bisphosphonates and/or denosumab in beneficiaries with bone metastases from breast, lung, or prostate cancer. For anti-emetic drugs, we evaluated prophylactic use of neurokinin-1 (NK1) antagonists and long-acting (LA) serotonin antagonists. For white blood cell growth factors (GCSFs), we evaluated prophylactic use in beneficiaries starting chemotherapy for breast, lung, or colorectal cancer; we separately evaluated use of biosimilar (vs originator) filgrastim. Analyses employed the difference-in-differences (DID) approach, excepting the filgrastim biosimilar analysis where we assessed the adoption trend. Results: There was no OCM impact on receipt of any bone supportive medication (denosumab or bisphosphonate) among beneficiaries with bone metastases; however, OCM led to a relative decrease in use of denosumab for breast cancer (DID = -5.0 percentage points [90% CI -7.1, -2.8]), prostate cancer (-4.0 percentage points [90% CI -5.9, -2.2]), and lung cancer (-4.1 percentage points [90% CI -7.4, -0.9]). In beneficiaries starting chemotherapy regimens with high or moderate emetic risk, OCM led to reductions in prophylactic use of NK1 antagonists and LA serotonin antagonists (e.g. 6.0 percentage point reduction in use of NK1 antagonists during high emetic risk chemotherapy [90% CI -9.0, -3.1]); there was no impact on antiemetic use during low emetic risk chemotherapy. There was no OCM impact on use of prophylactic WBC growth factors among beneficiaries receiving chemotherapy with high risk for febrile neutropenia (FN). Among beneficiaries receiving chemotherapy with intermediate risk for FN, OCM led to a 7.6 percentage point reduction in prophylactic GCSF use for patients with breast cancer (90% CI -12.6, -2.7); however, there was no OCM impact on prophylactic GCSF use in patients with lung or colorectal cancer. Among beneficiaries receiving filgrastim, OCM led to faster adoption of biosimilar vs. originator filgrastim (differential trend estimate 2.6%, 90% CI 1.0, 4.4). Conclusions: OCM led to reduced use of some high cost supportive care medications, with patterns suggesting more value-conscious care. Alternative payment models have potential to drive value-based changes in medication use during cancer care." @default.
• W3171550055 created "2021-06-22" @default.
• W3171550055 creator A5020433696 @default.
• W3171550055 creator A5022780815 @default.
• W3171550055 creator A5023329912 @default.
• W3171550055 creator A5035101687 @default.
• W3171550055 creator A5046270355 @default.
• W3171550055 creator A5048008109 @default.
• W3171550055 creator A5066655122 @default.
• W3171550055 creator A5068293939 @default.
• W3171550055 creator A5075264942 @default.
• W3171550055 creator A5083466901 @default.
• W3171550055 creator A5088183696 @default.
• W3171550055 date "2021-05-20" @default.
• W3171550055 modified "2023-09-27" @default.
• W3171550055 title "Impact of the Oncology Care Model on use of bone supportive medications, antiemetics, and growth factors." @default.
• W3171550055 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.1517" @default.
• W3171550055 hasPublicationYear "2021" @default.
• W3171550055 type Work @default.
• W3171550055 sameAs 3171550055 @default.
• W3171550055 citedByCount "0" @default.
• W3171550055 crossrefType "journal-article" @default.
• W3171550055 hasAuthorship W3171550055A5020433696 @default.
• W3171550055 hasAuthorship W3171550055A5022780815 @default.
• W3171550055 hasAuthorship W3171550055A5023329912 @default.
• W3171550055 hasAuthorship W3171550055A5035101687 @default.
• W3171550055 hasAuthorship W3171550055A5046270355 @default.
• W3171550055 hasAuthorship W3171550055A5048008109 @default.
• W3171550055 hasAuthorship W3171550055A5066655122 @default.
• W3171550055 hasAuthorship W3171550055A5068293939 @default.
• W3171550055 hasAuthorship W3171550055A5075264942 @default.
• W3171550055 hasAuthorship W3171550055A5083466901 @default.
• W3171550055 hasAuthorship W3171550055A5088183696 @default.
• W3171550055 hasConcept C121608353 @default.
• W3171550055 hasConcept C126322002 @default.
• W3171550055 hasConcept C143998085 @default.
• W3171550055 hasConcept C160735492 @default.
• W3171550055 hasConcept C162324750 @default.
• W3171550055 hasConcept C2776256026 @default.
• W3171550055 hasConcept C2776286101 @default.
• W3171550055 hasConcept C2776534028 @default.
• W3171550055 hasConcept C2776541429 @default.
• W3171550055 hasConcept C2776694085 @default.
• W3171550055 hasConcept C2777251235 @default.
• W3171550055 hasConcept C2780192828 @default.
• W3171550055 hasConcept C50522688 @default.
• W3171550055 hasConcept C530470458 @default.
• W3171550055 hasConcept C59491497 @default.
• W3171550055 hasConcept C71924100 @default.
• W3171550055 hasConceptScore W3171550055C121608353 @default.
• W3171550055 hasConceptScore W3171550055C126322002 @default.
• W3171550055 hasConceptScore W3171550055C143998085 @default.
• W3171550055 hasConceptScore W3171550055C160735492 @default.
• W3171550055 hasConceptScore W3171550055C162324750 @default.
• W3171550055 hasConceptScore W3171550055C2776256026 @default.
• W3171550055 hasConceptScore W3171550055C2776286101 @default.
• W3171550055 hasConceptScore W3171550055C2776534028 @default.
• W3171550055 hasConceptScore W3171550055C2776541429 @default.
• W3171550055 hasConceptScore W3171550055C2776694085 @default.
• W3171550055 hasConceptScore W3171550055C2777251235 @default.
• W3171550055 hasConceptScore W3171550055C2780192828 @default.
• W3171550055 hasConceptScore W3171550055C50522688 @default.
• W3171550055 hasConceptScore W3171550055C530470458 @default.
• W3171550055 hasConceptScore W3171550055C59491497 @default.
• W3171550055 hasConceptScore W3171550055C71924100 @default.
• W3171550055 hasFunder F4320332205 @default.
• W3171550055 hasIssue "15_suppl" @default.
• W3171550055 hasLocation W31715500551 @default.
• W3171550055 hasOpenAccess W3171550055 @default.
• W3171550055 hasPrimaryLocation W31715500551 @default.
• W3171550055 hasRelatedWork W2064471311 @default.
• W3171550055 hasRelatedWork W2348231456 @default.
• W3171550055 hasRelatedWork W2354050160 @default.
• W3171550055 hasRelatedWork W2367105124 @default.
• W3171550055 hasRelatedWork W2379009234 @default.
• W3171550055 hasRelatedWork W2379151083 @default.
• W3171550055 hasRelatedWork W2388730008 @default.
• W3171550055 hasRelatedWork W2603335165 @default.
• W3171550055 hasRelatedWork W2791179561 @default.
• W3171550055 hasRelatedWork W2773216875 @default.
• W3171550055 hasVolume "39" @default.
• W3171550055 isParatext "false" @default.
• W3171550055 isRetracted "false" @default.
• W3171550055 magId "3171550055" @default.
• W3171550055 workType "article" @default.